GLS2 is protumorigenic in breast cancers (2020)
Source: Oncogene. Unidade: IFSC
Subjects: NEOPLASIAS MAMÁRIAS, GLUTAMINA, METÁSTASE NEOPLÁSICA
ABNT
DIAS, Marilia M. et al. GLS2 is protumorigenic in breast cancers. Oncogene, v. 39, n. Ja 2020, p. 690-720, 2020Tradução . . Disponível em: https://doi.org/10.1038/s41388-019-1007-z. Acesso em: 04 nov. 2024.APA
Dias, M. M., Adamoski, D., Reis, L. M., Ascenção, C. F. R., Oliveira, K. R. S., Mafra, A. C. P., et al. (2020). GLS2 is protumorigenic in breast cancers. Oncogene, 39( Ja 2020), 690-720. doi:10.1038/s41388-019-1007-zNLM
Dias MM, Adamoski D, Reis LM, Ascenção CFR, Oliveira KRS, Mafra ACP, Bastos ACS, Quintero M, Cassago CG, Ferreira IM, Fidelis CHV, Rocco SA, Bajgelman MC, Stine Z, Berindan-Neagoe I, Calin GA, Ambrosio ALB, Dias SMG. GLS2 is protumorigenic in breast cancers [Internet]. Oncogene. 2020 ; 39( Ja 2020): 690-720.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1038/s41388-019-1007-zVancouver
Dias MM, Adamoski D, Reis LM, Ascenção CFR, Oliveira KRS, Mafra ACP, Bastos ACS, Quintero M, Cassago CG, Ferreira IM, Fidelis CHV, Rocco SA, Bajgelman MC, Stine Z, Berindan-Neagoe I, Calin GA, Ambrosio ALB, Dias SMG. GLS2 is protumorigenic in breast cancers [Internet]. Oncogene. 2020 ; 39( Ja 2020): 690-720.[citado 2024 nov. 04 ] Available from: https://doi.org/10.1038/s41388-019-1007-z